One of the clearest U.S. device-safety stories from the week of March 2 to March 9, 2026 was the FDA’s March 6 classification and posting of a confirmed recall involving certain MediHoney Wound and Burn products and specific lots of CVS Wound Gel made by Integra LifeSciences. The agency said the action involves removing certain devices from where they are used or sold after identifying issues that could raise infection risk and, in some cases, delay care if affected products cannot be used. For hospitals, wound clinics, distributors, and retail-adjacent care channels, the development matters because it combines a familiar postmarket problem—packaging and process-control failures—with a product category that is used broadly in routine wound management.
What happened is more than a routine update. On March 6, 2026, the FDA updated its communication to state that the Integra issue had been classified as a Class II recall, meaning the agency believes the affected devices may cause temporary or medically reversible adverse health consequences, or that the chance of serious harm is remote. The FDA’s recalls page lists the issue on March 6 as a confirmed recall, placing it squarely inside your requested one-week window. The agency also notes that it had first issued an Early Alert on January 22, 2026, before later updating the communication with the Class II recall designation.
The affected products include multiple MediHoney items across the wound-and-burn line, including calcium alginate dressings and sterile gel-in-tube products, as well as certain lots of CVS Wound Gel. FDA says Integra had already sent affected customers a letter on January 16 recommending that all MediHoney Wound and Burn products and certain CVS lots be removed from use or sale. The agency instructed customers not to use affected product, to identify and remove it from service immediately, and to quarantine impacted inventory. Distributors were told to stop further distribution, check traceability records, notify downstream customers, and collect affected product.
Why does this matter to the market? Because these are not niche implantables used in a handful of tertiary centers. Wound and burn dressings sit in a broad care pathway that can touch hospitals, outpatient wound centers, physician offices, long-term care environments, and retail-linked supply channels. FDA says the affected products are used to help treat burns and wounds by maintaining a moist wound environment and helping protect skin from breakdown, irritation, or damage. When a recall hits a high-use category like this, providers often have to move quickly to locate inventory, substitute product, update clinical staff, and prevent affected stock from being used in routine care settings where volume can be high and decentralized.
The clinical reason for the recall is also important. FDA said Integra identified packaging failures related to the MediHoney wound and burn products that could lead to a breach in the sterile barrier. If a product with a compromised sterile barrier is used, the agency says it could lead to patient infection. FDA separately said Integra identified production and process-control issues for certain CVS Wound Gel products, which may also lead to infection if used. In both cases, the inability to use the device due to these issues may delay care. That combination—possible contamination risk plus immediate loss of usable stock—is exactly the kind of event that creates downstream stress for wound-care supply planning.
The harm signal is not theoretical. FDA reported that, as of December 19, 2025, Integra had reported 11 serious injuries related to MediHoney Wound and Burn products and three serious injuries related to CVS Wound Gel products, with no deaths associated with the issue. MedTech Dive’s January coverage underscored the same point, reporting that the recall followed serious injuries tied to packaging failures that could compromise sterility. That earlier coverage also noted that Integra had written to customers roughly five months after recalling other wound and burn devices over sterile-barrier sealing concerns, giving the event a broader quality-and-operations context rather than making it look like a standalone isolated incident.
Who is impacted most? First, hospital materials managers and wound-care teams need to ensure affected stock is removed and substitutes are available. Second, distributors and retail-linked channels are affected because the recall spans both branded MediHoney products and certain CVS-labeled wound gel lots, increasing the complexity of inventory tracing. Third, Integra and its channel partners face renewed scrutiny over quality systems, packaging integrity, and recall execution. In practice, this type of event can ripple beyond direct clinical risk: it can interrupt routine purchasing, increase demand for alternative dressings, and force providers to rebalance contracts and preferred-product lists while they wait for replacement supply.
From a surgical and procedural market standpoint, the recall is a reminder that supply-chain risk does not come only from complex capital devices. Lower-profile consumables and wound products can still create operational disruption when they are widely used, stocked across multiple care sites, and tied to infection-control expectations. The FDA’s current recalls and early alerts page shows a steady stream of device actions across care settings, and the March 6 Integra posting fits that broader environment of heightened postmarket vigilance. For providers, that means recall readiness now requires tighter lot tracking, faster quarantine procedures, and clearer substitution protocols even in categories that may not always receive executive attention.
